journal article·2025-03-25

Probing the Structural Elements of Polysaccharide Adjuvants for Enhancing Respiratory Mucosal Response: From Surmounting Multi-Obstacles to Eliciting Cascade Immunity

Zhixiang Cui, Hezhi Wang, Lu Qin, Ye Yuan, Jingwen Xue, Yalin An, Le Sun, Renfang Zhu, Qingyu Li, Yi Wang, Shuman Cui, Xuanguang Zhan, Qiyao Zhai, Haiyan Sun, Xin Zhang, Jian Guan, Chang Liu, Shirui Mao

ACS Nano· Volume 19· Issue 11
Publisher page

Abstract

The immunomodulatory effects and excellent tolerability of polysaccharides make them optimal candidates for pulmonary vaccine adjuvants. Yet, the structure-immunostimulatory activity relationship of polysaccharides remains unrevealed. Here, we developed nanovaccines decorated with four polysaccharides of distinct structures─hyaluronic acid (HA), pectin (PC), chondroitin sulfate (SC), and heparan sulfate (SH)─all sharing similar particle sizes and zeta potential. Polysaccharides containing sulfate groups (SC, SH) exhibited superior efficacy in overcoming natural inhalation barriers and recruiting dendritic cells (DC). DC stimulation assays revealed that HA and SH significantly upregulated the expression of costimulation signals, with IL-6 secretion rising over 8.7-fold compared to pure OVA. Fluorescence resonance energy transfer demonstrated their detachment within the lysosomal microenvironment, thereby enhancing antigen cross-presentation. However, in vivo findings only showed that SH upregulated CCR7 chemokine and swiftly migrated to lymph nodes. Molecular docking and Western blot analyses further elucidated the involvement of the TLR─MyD88─TRAF6─NF-κB/MAPK/IRF-7 signaling pathways. Notably, SH-modified nanovaccines induced a more robust cellular and humoral immune response with the potential for immune memory. This study confirms that sulfate groups in polysaccharides enhance immune activation and that combining sulfate with acetyl groups offers a promising adjuvant configuration for augmenting mucosal, cellular, and humoral immunity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pediatric health and respiratory diseases · Immune Response and Inflammation · Polysaccharides and Plant Cell Walls

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Shenyang Key Laboratory of Intelligent Mucosal Drug Delivery Systems

Shenyang Pharmaceutical University

Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education

Funding

National Key Research and Development Program of China · Department of Education of Liaoning Province

References (49)

Show source-provided references
1. 10.1080/17425247.2022.213176710.1080/17425247.2022.2131767 ↗
2. 10.1016/j.molmed.2023.01.00310.1016/j.molmed.2023.01.003 ↗
3. 10.1038/s41565-020-0737-y10.1038/s41565-020-0737-y ↗
4. 10.1021/acs.molpharmaceut.1c0044710.1021/acs.molpharmaceut.1c00447 ↗
5. 10.1016/j.addr.2015.11.00510.1016/j.addr.2015.11.005 ↗
6. 10.1016/j.jconrel.2019.04.02510.1016/j.jconrel.2019.04.025 ↗
7. 10.1021/acsami.8b1239310.1021/acsami.8b12393 ↗
8. 10.1016/j.apsb.2022.08.01510.1016/j.apsb.2022.08.015 ↗
9. 10.1016/j.ddtec.2020.09.00510.1016/j.ddtec.2020.09.005 ↗
10. 10.1517/17460441.2015.106719810.1517/17460441.2015.1067198 ↗
11. 10.5582/ddt.2015.0102510.5582/ddt.2015.01025 ↗
12. 10.1016/j.jddst.2023.10518410.1016/j.jddst.2023.105184 ↗
13. 10.1016/j.bioactmat.2021.03.00810.1016/j.bioactmat.2021.03.008 ↗
14. 10.1016/j.carbpol.2023.12103810.1016/j.carbpol.2023.121038 ↗
15. 10.3389/fimmu.2024.140621310.3389/fimmu.2024.1406213 ↗
16. 10.1016/j.carbpol.2015.05.07910.1016/j.carbpol.2015.05.079 ↗
17. 10.1016/j.carbpol.2008.12.01510.1016/j.carbpol.2008.12.015 ↗
18. 10.1016/j.carbpol.2017.12.00910.1016/j.carbpol.2017.12.009 ↗
19. 10.1016/j.jconrel.2023.08.01910.1016/j.jconrel.2023.08.019 ↗
20. 10.1002/adfm.20210891710.1002/adfm.202108917 ↗
21. 10.1016/j.jconrel.2018.07.00110.1016/j.jconrel.2018.07.001 ↗
22. 10.1016/j.addr.2017.12.00210.1016/j.addr.2017.12.002 ↗
23. 10.1016/j.jconrel.2007.10.02310.1016/j.jconrel.2007.10.023 ↗
24. 10.1016/j.ejpb.2007.01.01010.1016/j.ejpb.2007.01.010 ↗
25. 10.1016/j.jconrel.2023.02.01110.1016/j.jconrel.2023.02.011 ↗
26. 10.1021/acsami.1c2306910.1021/acsami.1c23069 ↗
27. 10.1016/j.addr.2011.05.02110.1016/j.addr.2011.05.021 ↗
28. 10.1016/j.smim.2011.01.00410.1016/j.smim.2011.01.004 ↗
29. 10.1039/D1BM02021H10.1039/D1BM02021H ↗
30. 10.1002/adhm.20190047410.1002/adhm.201900474 ↗
31. 10.1021/acs.accounts.9b0017710.1021/acs.accounts.9b00177 ↗
32. 10.1016/j.jconrel.2015.12.00810.1016/j.jconrel.2015.12.008 ↗
33. 10.1007/s11095-012-0891-510.1007/s11095-012-0891-5 ↗
34. 10.1073/pnas.181640111510.1073/pnas.1816401115 ↗
35. 10.1016/j.jconrel.2022.10.01610.1016/j.jconrel.2022.10.016 ↗
36. 10.1016/j.biomaterials.2016.12.02110.1016/j.biomaterials.2016.12.021 ↗
37. 10.3390/pharmaceutics1302014210.3390/pharmaceutics13020142 ↗
38. 10.1038/ni.186310.1038/ni.1863 ↗
39. 10.1016/j.apsb.2022.11.02210.1016/j.apsb.2022.11.022 ↗
40. 10.1016/j.scib.2020.07.01310.1016/j.scib.2020.07.013 ↗
41. 10.1186/s12951-023-01782-w10.1186/s12951-023-01782-w ↗
42. 10.1038/nature0973710.1038/nature09737 ↗
43. 10.1016/j.jconrel.2020.10.06610.1016/j.jconrel.2020.10.066 ↗
44. 10.1021/acsami.1c0070610.1021/acsami.1c00706 ↗
45. 10.1016/j.cytogfr.2010.11.00210.1016/j.cytogfr.2010.11.002 ↗
46. 10.1038/mi.2009.10010.1038/mi.2009.100 ↗
47. 10.1039/D0BM01529F10.1039/D0BM01529F ↗
48. 10.1016/j.jconrel.2024.01.02910.1016/j.jconrel.2024.01.029 ↗
49. 10.1038/ncomms661510.1038/ncomms6615 ↗